The European Union’s Medicines Regulation Agency is investigating cases of blood clots among four individuals who received the Johnson & Johnson coronavirus vaccine, although a link between the two is not yet clear.
The European Medicines Agency (EMA) said on Friday that serious cases of ‘unusual low-blood clots’ had been reported in four people who had received the Johnson & Johnson vaccine. according to Reuters.
Three of the cases occurred in the U.S. during vaccination of vaccines, while one person who participated in Johnson & Johnson’s clinical trial had a coagulation disorder.
According to the Centers for Disease Control and Prevention (CDC), about five million people in the US have already received the vaccine for Johnson & Johnson.
The company said in a statement on Friday that it was aware of the reports of blood clots and was working with regulators to review safety data.
“At present, no clear causal link has been established between these rare events and the Janssen COVID-19 vaccine,” Johnson & Johnson told Reuters.
The Hill contacted the vaccine developer for additional information.
The reports come because there is already great concern about blood clots reported in individuals who received the AstraZeneca vaccine, which is not federally authorized for emergency use in the US.
An EMA safety committee said this on Wednesday a “possible link” exists between the AstraZeneca vaccine and rare blood clots, but added that the benefits of receiving the shot outweigh the potential risks.
The committee said this Uncommon low-platelet blood clots should be listed as very rare side effects of the vaccine, although this has not put any new restrictions on vaccination.
However, some European countries have imposed restrictions on the distribution of the AstraZeneca vaccine, including the recommendation of young age groups to receive it.
Most cases of blood clots were reported within two weeks of receiving the AstraZeneca shot among women under the age of 60.
The Johnson & Johnson’s and AstraZeneca vaccines are two of the four approved in Europe, although the implementation of Johnson & Johnson’s single dose has not yet begun across the region.